‘Potentially disease ridden' bushmeat stopped at Detroit Metro Airport
**WARNING: This article contains images that some readers may find disturbing. Reader's discretion is advised**
U.S. Customs and Border Protection (CBP) have stopped 'potentially disease ridden' bushmeat twice in one week at Detroit Metropolitan Airport.
ADVERTISEMENT
The incident took place last month. CBP said bushmeat is meat from wild animals, which can include bats, non-human primates, and cane rats from certain regions. It's illegal to import into the U.S. and poses a significant disease risk.
'These recent bushmeat interceptions are significant in bringing attention to the illegal importation of bushmeat through our ports of entry,' said Fadia Pastilong, port director.
'This also showcases how we work with our partner agencies to prevent a potential disease outbreak.'
The meat was seized and turned over to the Centers for Disease Control and Prevention. Each traveller was fined $300 for undeclared agricultural items.
CBP said rodent-type bushmeat interceptions are sporadic at Detroit Metropolitan Airport, but primate interceptions are much rarer. Bushmeat is considered a cultural delicacy and often consumed raw, or with minimal processing, which can increase disease. That includes ebola, mpox, and other emerging diseases.
'We routinely find various agriculture items and oddities – live giant snails, animal skills, and exotic food items – but most times it's not a malicious act,' said Marty C. Raybon, director of field operations.
'Despite this, it's our duty to protect the homeland and preventing certain food and animal products from entering the U.S. is essential to public health.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a few seconds ago
- CTV News
Father of Boston Celtics star Jaylen Brown arrested and charged with attempted murder
Jaylen Brown is a four-time NBA All-Star after getting drafted by the Boston Celtics in the first round in 2016. (via CNN Newsource) Quenton Marselles Brown, the father of Boston Celtics star Jaylen Brown, has been arrested and charged with attempted murder after allegedly stabbing a man multiple times in Las Vegas. The incident took place on Wednesday in a parking lot after Brown allegedly dinged the car of the victim, according to a report from the Las Vegas Metropolitan Police Department. Brown and the victim then got into an altercation before Brown reportedly pulled out what appeared to be a knife and stabbed the victim repeatedly, witnesses told police. The victim was transported to a hospital where an attending physician said the man is in critical condition after sustaining 'a stab wound in the middle of his back, a stab wound in his upper right chest clavicle area, a defensive wound to his left hand that penetrated to his tendons, a slice wound that necessitated a partial gastrectomy to remove part of his digestive system, eviscerated bowels, and a broken right rib that may require surgery to repair,' according to the police report. Brown is being held at the Clark County Detention Center, according to jail records. It was not immediately clear if Brown has a lawyer. A source confirmed to AP that Brown is the father of the Boston Celtics basketball player. CNN has reached out to the Celtics for comment.
Globe and Mail
30 minutes ago
- Globe and Mail
Influenza Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment. Influenza Pipeline Summary DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza; ENA Respiratory's INNA-051, an immunomodulatory intranasal spray in Phase IIa; Codagenix's CODA-VAX H1N1, a universal live-attenuated flu vaccine in Phase I; and AlloVir's ALVR106, an allogeneic, off-the-shelf VST therapy targeting multiple respiratory viruses. The report further analyzes over 120+ pipeline drugs across various clinical stages, including Phase III, II, I, preclinical, and discovery. It categorizes therapies by route of administration (oral, intravenous, intranasal, inhalation, subcutaneous, etc.), molecule type (antibodies, vaccines, peptides, proteins, immunotherapies, small molecules, stem cells), and product type (mono, combination, or both). Moderna currently leads the late-stage pipeline, showcasing the growing diversity and innovation in influenza treatment strategies. Key Takeaways from the Influenza Pipeline Report Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment. In August 2025, AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination. AstraZeneca launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST®(Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. In July 2025, SK bioscience, a global innovative vaccine and biotech company dedicated to advancing human health from prevention to cure, announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. This candidate integrates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu', to improve protective efficacy. SK bioscience previously applied adjuvant technology in its COVID-19 vaccine, 'SKYCovione', and now aims to extend this approach to influenza vaccines as part of its broader platform strategy. In July 2025, GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. In March 2025, Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others. Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs Influenza Emerging Drugs · mRNA-1010 (Moderna): A Phase III vaccine targeting WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria). Encodes HA glycoproteins to generate broad protection against seasonal influenza. · SAB-176 (SAB Biotherapeutics): A quadrivalent polyclonal antibody therapy developed via DiversitAb™ platform. Designed to neutralize Type A and B influenza viruses, showing broad protection potential. Targeted for severe cases and high-risk groups like elderly and immunocompromised patients. · INNA-051 (ENA Respiratory): An intranasal immunomodulatory spray in Phase IIa trials. Intended for pre- and post-exposure prophylaxis of respiratory viral infections, with potential use across multiple viruses and at-risk populations. · CODA-VAX H1N1 (Codagenix): A live-attenuated universal flu vaccine in Phase I trials. Shows promise for multi-season protection by targeting conserved viral antigens and is being developed into a quadrivalent formulation. · ALVR106 (AlloVir): An allogeneic, off-the-shelf VST therapy in preclinical development. Targets RSV, influenza, PIV, and hMPV, with in vitro data showing strong antiviral activity and potential safety benefits. Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs Key influenza Companies: The following are the leading companies in the influenza market. These companies collectively hold the largest market share and dictate industry trends. Influenza Pipeline Drugs by Route of Administration Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous • Intravenous/ Subcutaneous • NA • Oral • Oral/intranasal/subcutaneous • Parenteral • Subcutaneous Influenza Pipeline Drugs by Molecule Types Influenza Products have been categorized under various Molecule types such as • Antibody • Antisense oligonucleotides • Immunotherapy • Monoclonal antibody • Peptides • Protein • Recombinant protein • Small molecule • Stem Cell • Vaccine Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers Scope of the Influenza Pipeline Report Coverage- Global Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Table of Content 1. Influenza Report Introduction 2. Influenza Executive Summary 3. Influenza Overview 4. Influenza- Analytical Perspective In-depth Commercial Assessment 5. Influenza Pipeline Therapeutics 6. Influenza Late Stage Products (Phase II/III) 7. Influenza Mid Stage Products (Phase II) 8. Influenza Early Stage Products (Phase I) 9. Influenza Preclinical Stage Products 10. Influenza Therapeutics Assessment 11. Influenza Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Influenza Key Companies 14. Influenza Key Products 15. Influenza Unmet Needs 16 . Influenza Market Drivers and Barriers 17. Influenza Future Perspectives and Conclusion 18. Influenza Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
CTV News
an hour ago
- CTV News
Defamation case against Fox News highlights role of its hosts in promoting 2020 election falsehoods
NEW YORK — Court papers in a voting technology company's US$2.7 billion defamation lawsuit against Fox News point to Maria Bartiromo, Lou Dobbs and Jeanine Pirro as leaders in spreading false stories about election fraud in the weeks after Democrat Joe Biden's victory over U.S. President Donald Trump in 2020. Arguments for summary judgment by Smartmatic were filed in lightly redacted form this week at the New York Supreme Court. It's like a bad rerun for Fox: Similar revelations about its conduct following the 2020 election came in a lawsuit by another company falsely accused of doctoring votes, Dominion Voting Systems. Fox agreed to pay Dominion US$787 million in a 2023 settlement after the judge found it was 'CRYSTAL CLEAR' that none of the claims against the voting system company were true. In short: Fox let Trump aides spread conspiracy theories despite knowing they were false because it was what their viewers wanted to hear. Fox was trying to hold on to viewers who were angry at the network for saying Biden had won the election. Fox said it was covering a newsworthy story. It accuses the London-based company, which had only Los Angeles County as a client for the 2020 election, of exaggerating its claims of damages in the hope of receiving a financial windfall. Maria Bartiromo, Lou Dobbs and Jeanine Pirro From left: Maria Bartiromo in 2016, Lou Dobbs in 2017, Jeanine Pirro in 2015. (AP) Pirro now working in the second Trump administration The focus on Pirro is noteworthy because the former Fox personality now serves in Trump's second administration as U.S. attorney in Washington, D.C. Smartmatic, relying on emails and text messages revealed as part of the case, said Pirro was using her position as a Fox host in 2020 to help Trump and persuade him to pardon her ex-husband, Albert Pirro, who was convicted of conspiracy and tax evasion. Trump pardoned him before leaving office in 2021. In a text to then-Republican National Committee chairwoman Ronna McDaniel in September 2020, Pirro said, 'I'm the No. 1 watched show on news cable all weekend. I work so hard for the President and the party,' Smartmatic said in court papers. One of her own producers, Jerry Andrews, called Pirro a 'reckless maniac,' Smartmatic said. He texted after one of her shows in November that it was 'rife (with) conspiracy theories and bs and is yet another example of why this woman should never be on live television.' The court papers said Pirro also suggested 'evidence' of supposed fraud to Trump lawyer Sidney Powell that she could use on a television appearance — material that also was spread by Bartiromo. Bartiromo still works at Fox, and in 2020 had shows on both the news channel and Fox Business Network. The court papers uncovered messages showing her desire to help Trump: 'I am very worried. Please please please overturn this. Bring the evidence, I know you can,' she texted to Powell. Dobbs, whose business show was canceled by Fox in February 2021, texted to Powell four days after the election, saying 'I'm going to do what I can to help stop what is now a coup d'etat in (its) final days — perhaps moments," a reference to Biden's victory. Dobbs died in 2024. U.S. Attorney for the District of Columbia Jeanine Pirro speaks during a newss conference first about the indictment of an alleged Haitian gang leader and then about murders in Washington in 2024 and 2025, Tuesday, Aug. 12, 2025, at the U.S. Attorney... U.S. Attorney for the District of Columbia Jeanine Pirro speaks during a newss conference first about the indictment of an alleged Haitian gang leader and then about murders in Washington in 2024 and 2025, Tuesday, Aug. 12, 2025, at the U.S. Attorney's office in Washington. (AP Photo/Jacquelyn Martin) A central figure in Fox's 'pivot' Smartmatic portrayed Pirro as a central figure in Fox's 'pivot' to deemphasize Biden's victory because it angered Trump fans. Instead, the network found that ratings jumped whenever claims of election fraud were discussed, it said. As in the Dominion case, the discovery process helped Smartmatic find messages and statements that seem embarrassing in retrospect. For example, in early December, Fox's Jesse Watters texted colleague Greg Gutfeld that 'Think of how incredible our ratings would be if Fox went ALL in on STOP THE STEAL.' Fox, in a response to the newly-revealed court papers, pointed to an ongoing corruption case involving Smartmatic and its executives, including a claim by federal prosecutors that it used money from the sale of voting machines to set up a 'slush fund' for bribing foreign officials. 'The evidence shows that Smartmatic's business and reputation were badly suffering long before any claims by U.S. President Trump's lawyers on Fox News and that Smartmatic grossly inflated its damage claims to generate headlines and chill free speech,' Fox said. 'Now, in the aftermath of Smartmatic's executives getting indicted for bribery charges, we are eager and ready to continue defending our press freedoms.' Smartmatic has already settled similar defamation claims against Newsmax and One America News Network in relation to their post-2020 election coverage. ___ David Bauder writes about the intersection of media and entertainment for the AP. Follow him at and David Bauder, The Associated Press
